每经AI快讯，2月25日，昂利康(002940.SZ)公告称，公司收到国家药品监督管理局签发的多潘立酮片 《药品补充申请批准通知书》，通过仿制药质量和疗效一致性评价。该药品用于消化不良、腹胀、嗳 气、恶心、呕吐、腹部胀痛。通过一致性评价将提升公司市场竞争力，但销售情况受政策、市场环境等 因素影响，存在不确定性。 （文章来源：每日经济新闻） ...

证券代码：605199 证券简称：ST葫芦娃 公告编号：2026-011 海南葫芦娃药业集团股份有限公司关于获得吸入用异丙托溴铵溶液药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管理局（以下简称"国家 药监局"）核准签发的关于吸入用异丙托溴铵溶液《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：吸入用异丙托溴铵溶液 剂型：吸入制剂 注册分类：化学药品4类 规格：2ml：0.25mg（按C??H??BrNO?计）、2ml：0.5mg（按C??H??BrNO?计） 上市许可持有人：海南葫芦娃药业集团股份有限公司 受理号：CYHS2403031、CYHS2403032 药品批准文号：国药准字H20263362、国药准字H20263363 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。 二、药品研发及相关 2ml：0.25mg的吸入用异丙托溴铵溶液可与 ...

Core Viewpoint - The announcement highlights that Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.'s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval for its injectable penicillin sodium product, which is expected to enhance its market competitiveness [1] Group 1 - The product, injectable penicillin sodium 0.96g (1.6 million units), has passed the consistency evaluation for generic drug quality and efficacy [1] - The research and development expenses incurred by Tianxin Pharmaceutical for this product amount to approximately RMB 2.5926 million (unaudited) [1] - The approval is seen as a positive development for the company's product portfolio, potentially increasing its market share [1]

Core Viewpoint - Recently, Harbin Pharmaceutical Group Co., Ltd. (stock code: 600664) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, received a "Drug Supplement Application Approval Notice" from the National Medical Products Administration for injectable Cefotaxime Sodium, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The drug is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, and gynecological infections [1] - As of the announcement date, there are a total of 239 production approvals for injectable Cefotaxime Sodium in China, with 37 manufacturers having passed the consistency evaluation [1] - The domestic sales revenue for the drug is projected to be 1.55 billion yuan in 2024, with 889 million yuan expected in the first three quarters of 2025 [1] Group 2 - The company has invested approximately 8.1573 million yuan in research and development for the consistency evaluation project of this drug [1]

Core Viewpoint - North China Pharmaceutical Co., Ltd. has announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Cefprozil Tablets (0.25g) from the National Medical Products Administration, which is expected to enhance the company's product portfolio and market competitiveness [1][6]. Group 1: Drug Registration Details - The Drug Registration Certificate for Cefprozil Tablets (0.25g) was approved by the National Medical Products Administration [1]. - Cefprozil is a second-generation cephalosporin antibiotic, initially developed by Bristol-Myers Squibb in 1991, and was the first oral cephalosporin approved by the FDA for treating pediatric otitis media and sinusitis [1][2]. Group 2: Indications and Market Situation - The approved indications for Cefprozil in China include treatment for upper respiratory infections, lower respiratory infections, and skin and soft tissue infections caused by sensitive bacteria [2]. - Currently, there are 10 companies, including Huamin, that hold the Drug Registration Certificate for Cefprozil Tablets (0.25g) in China. Sales figures for Cefprozil Tablets in sample hospitals from 2023 to the first three quarters of 2025 are reported as 141.7 million, 134.99 million, and 74.22 million yuan respectively [5]. Group 3: Research and Development Investment - The cumulative R&D investment for the drug has reached 14.6458 million yuan (unaudited) [3]. Group 4: Future Prospects - Following the receipt of the Drug Registration Certificate, the company can arrange for production and market the product [4].

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for the generic drug Tramadol Hydrochloride Tablets (50mg) [1][2]. Group 1: Drug Approval Details - The drug name is Tramadol Hydrochloride Tablets, in tablet form, with a specification of 50mg [1]. - The approval notice number is 2026B00624, and the drug is classified as a chemical drug [1]. - The approval includes changes to the prescription, manufacturing process, production batch, quality standards, and shelf life [1]. Group 2: Market Context - The original drug has not been marketed in China, but there are currently eight generic versions approved, with three having passed the consistency evaluation [2]. - Beijing Huasu is the third domestic company to receive approval for this drug's consistency evaluation [2]. Group 3: Financial Investment - The total research and development investment for the consistency evaluation project of Tramadol Hydrochloride Tablets has reached approximately 5.9 million yuan [3]. Group 4: Impact on Company Performance - The approval is expected to enhance the market competitiveness of the drug and positively impact the company's operating performance [5]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug development, manufacturing, and sales processes [5].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Tacrolimus capsules (0.5mg, 1mg), which are potent immunosuppressants used to prevent organ rejection after liver or kidney transplants [1] Group 1 - The Tacrolimus capsules were originally submitted for registration by Jiangsu Hechen Pharmaceutical Co., Ltd. in June 2024 and received a drug registration acceptance number [1] - During the review period, there was a change in the drug registration applicant, with the company becoming the marketing authorization holder [1] - The drug was approved on January 2026, and it is considered to have passed the consistency evaluation of quality and efficacy for generic drugs [1]

Core Viewpoint - The company has received approval for the production of Loxoprofen Sodium Gel Patch, which is expected to enhance its product line in orthopedic medications and improve its competitive position in the market [1][3]. Group 1: Drug Registration and Details - The company's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch from the National Medical Products Administration [1]. - Loxoprofen Sodium Gel Patch is indicated for the treatment of osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The total investment in this drug project, including research and development, has reached 7.0366 million yuan (approximately 1.01 million USD) as of the announcement date [1]. Group 2: Market Situation of Similar Drugs - A total of 15 companies in China have obtained drug registration certificates for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [2]. - According to Moen Pharmaceutical data, the total sales of Loxoprofen Sodium Gel Patch in hospitals for the first three quarters of 2025 reached 1.349 billion yuan (approximately 190 million USD), with retail sales in physical pharmacies amounting to 142 million yuan (approximately 20 million USD) in the first half of 2025 [2]. - Projected sales for 2024 are expected to be 1.709 billion yuan (approximately 240 million USD) in hospitals and 280 million yuan (approximately 40 million USD) in retail pharmacies [2]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch will enrich the company's product line for orthopedic diseases, which already includes products like Xuanqi Jianguo Tablets and Tenghuang Jianguo Tablets [3]. - This new product is anticipated to enhance the company's competitiveness in the orthopedic medication market and improve overall profitability [3]. - The company emphasizes the importance of drug research and development while maintaining strict quality control in the manufacturing and sales processes [3].

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, allowing for production and sales, which enhances its product line in orthopedic medications and competitive position in the market [1][4]. Group 1: Drug Registration and Details - The Drug Registration Certificate for Loxoprofen Sodium Gel Patch was approved by the National Medical Products Administration on January 23, 2026 [1]. - Loxoprofen Sodium Gel Patch is indicated for osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis [1]. Group 2: Market Situation - As of the announcement date, 15 companies in China have obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [3]. - According to Moen Pharmaceutical data, the total hospital sales of Loxoprofen Sodium Gel Patch reached 1.349 billion yuan in the first three quarters of 2025, with retail sales in physical pharmacies amounting to 142 million yuan in the first half of 2025 [3]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch enriches the company's product line for orthopedic diseases and enhances its competitiveness in the market, potentially improving overall profitability [4]. - The company has invested a total of 7.0366 million yuan in the drug project, including research and development and technology transfer [2]. - The company emphasizes the importance of drug research and development, maintaining strict quality control in the drug development, manufacturing, and sales processes [4].

Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. has received approval for the supplementary application of Diflunisal tablets, which enhances the company's product line and market competitiveness [1][5]. Group 1: Drug Approval Details - Drug Name: Diflunisal Tablets [2][3] - Dosage Form: Tablet [2][3] - Specifications: 0.25g and 0.5g [2][3] - Registration Category: Chemical Drug [2][3] - License Holder and Manufacturer: Zhejiang Shapuaisi Pharmaceutical Co., Ltd. [2][3] - Approval Conclusion: The drug has passed the consistency evaluation of generic drug quality and efficacy [1][2]. Group 2: R&D Investment - The cumulative R&D investment for the Diflunisal tablet project is approximately 7.1492 million RMB [4]. Group 3: Market Impact - The approval of Diflunisal tablets is expected to enrich the company's product line and enhance the market competitiveness of this product [5].